NLRP3 and arthritic joint disease: GSK-3β inhibitor TDZD-8 treatment suppresses spinal Bax and DHODH mediated mitochondrial ROS levels, inhibits NF-κB mediated NLRP3 inflammation activation, and alleviates arthritis pain (Fig 6).